ClinicalTrials.gg
CompletedNCT02589626Updated Jan 7, 2019Results posted

Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

A Phase 4 interventional study of empagliflozin 10mg and empagliflozin 25 mg in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 16 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-01-07.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Enrollment
74th of 130
65 · median 79
Started
2015
with 4 others
Phase 4
50 of 130
11 open now
Registered
35th of 130
by date
Lead sponsor
37 of 130
Boehringer Ingelheim

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 74th largest by enrollment, is one of 5 that started in 2015, is one of 50 in phase 4, and was the 35th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a multi-center, randomised, double-blind, parallel-group, safety and efficacy study of empagliflozin as add-on to GLP-1 RA in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic control

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of type 2 diabetes mellitus
  • Male and female patients on diet and exercise regimen who are pre-treated with Liraglutide at 0.9 mg/day alone for at least 10 weeks prior to screening must be >=7.0% and \<=10.0% at screening
  • Male and female patients on diet and exercise regimen who are pre-treated with Liraglutide at 0.9 mg/day and one of oral antidiabetic drug (OAD) for at least 10 weeks prior to Visit 1 must be >=7.0% and \<=9.0% at screening and >=7.0% and \<=10.0% at placebo run-in
  • Male and female patients on diet and exercise regimen who are pre-treated with OAD alone for at least 10 weeks prior to Visit 1 must be >=7.0% and \<=10.0% at both screening and placebo run-in
  • Age at must be >=20 years
  • at screening must be \<=40 kg/m2
  • Further inclusion criteria apply

Exclusion criteria

Exclusion criteria:

  • Uncontrolled hyperglycaemia with a glucose values >270 mg/dL (>15.0 mmol/L) after an overnight fast during switch/washout/placebo run-in period and confirmed by a second measurement
  • Patients who are drug-naïve at screening visit or treat with any of insulin, thiazolidine dione, sodium-glucose co-transporter 2 (SGLT-2) inhibitor within 10 weeks prior to .
  • Acute coronary syndrome, stroke or within 12 weeks prior to informed consent
  • Indication of liver disease, defined by serum levels of either , aspartate aminotransferase, or alkaline phosphatase above 3 x as determined during screening and/or switch/washout/placebo run-in period
  • Impaired renal function, defined as estimated (eGFR) \<45 mL/min/1.73m2 (Japanese equation) as determined during screening and/or switch/washout/placebo run-in period
  • Further exclusion criteria apply
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
65 participants (actual)

Study arms

  • Experimental
    empagliflozin 10 mg

    empagliflozin 10 mg tablet and placebo matching empagliflozin 25 mg tablet

    Drug: empagliflozin 10mg · Drug: Placebo

  • Experimental
    empagliflozin 25 mg

    empagliflozin 25 mg tablet and placebo matching empagliflozin 10 mg tablet

    Drug: empagliflozin 25 mg · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With Drug-related Adverse Events (AEs) During 52 Weeks of Treatment

    Percentage of patients with drug-related Adverse events (AEs) during 52 weeks of treatment are presented

    Time frame: 52 weeks

Secondary outcomes

  1. Change From Baseline in HbA1c After 52 Weeks of Treatment

    Change from baseline in HbA1c after 52 weeks of treatment is presented. Means presented are the adjusted means.

    Time frame: baseline and 52 weeks

07

Results

Posted Jan 7, 2019

Participant flow

Patients were entered in the trial and randomised in a 1:1 ratio to receive treatment.

Participant flow — Overall Study
MilestoneEmpagliflozin 10 mgEmpagliflozin 25 mg
Started3233
Completed2931
Not completed32
Withdrew: Other than the reason specified10
Withdrew: Withdrawal by subject11
Withdrew: Adverse event11

Outcome measures

PrimaryPercentage of Patients With Drug-related Adverse Events (AEs) During 52 Weeks of Treatment

Percentage of patients with drug-related Adverse events (AEs) during 52 weeks of treatment are presented

Time frame:
52 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients With Drug-related Adverse Events (AEs) During 52 Weeks of Treatment
Percentage of participantsEmpagliflozin 10 mgEmpagliflozin 25 mg
Percentage of Patients With Drug-related Adverse Events (AEs) During 52 Weeks of Treatment9.421.2
SecondaryChange From Baseline in HbA1c After 52 Weeks of Treatment

Change from baseline in HbA1c after 52 weeks of treatment is presented. Means presented are the adjusted means.

Time frame:
baseline and 52 weeks
Reported as:
Mean · % of HbA1c
Change From Baseline in HbA1c After 52 Weeks of Treatment
% of HbA1cEmpagliflozin 10 mgEmpagliflozin 25 mg
Change From Baseline in HbA1c After 52 Weeks of Treatment-0.55 ± 0.15-0.77 ± 0.14

Adverse events

Collected over All AEs which occurred through the treatment phase and throughout the residual effect period (REP); up to 53 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Empagliflozin 10 mg0/32 (0%)2/32 (6.3%)10/32 (31.3%)
Empagliflozin 25mg0/33 (0%)1/33 (3%)15/33 (45.5%)
Most frequent serious events
Most frequent serious events
EventEmpagliflozin 10 mgEmpagliflozin 25mg
Loss of consciousnessNervous system disorders1/320/33
Large intestine polypGastrointestinal disorders1/320/33
Angina unstableCardiac disorders0/321/33
Most frequent other events
Most frequent other events
EventEmpagliflozin 10 mgEmpagliflozin 25mg
Viral upper respiratory tract infectionInfections and infestations10/3211/33
InfluenzaInfections and infestations0/323/33
PeriodontitisInfections and infestations0/322/33
PharyngitisInfections and infestations0/322/33
Vulvovaginal candidiasisInfections and infestations0/322/33
VertigoEar and labyrinth disorders0/322/33
FallInjury, poisoning and procedural complications1/322/33

Baseline characteristics

Full analysis set: The full analysis set (FAS) consisted of all patients in the treated set (TS) who were treated with at least 1 dose of the randomised study drug and had a baseline HbA1c assessment. The assignment of patients to treatment groups was based on the randomised study drug at time of randomisation.

Age, Continuous
Age, Continuous(years)Empagliflozin 10 mgEmpagliflozin 25 mgTotal
Mean55.6 ± 9.858.9 ± 9.357.3 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Empagliflozin 10 mgEmpagliflozin 25 mgTotal
Female61117
Male262248
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Empagliflozin 10 mgEmpagliflozin 25 mgTotal
American Indian or Alaska Native000
Asian323365
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Baseline glycosylated haemoglobin A1c (HbA1c)
Baseline glycosylated haemoglobin A1c (HbA1c)(% of HbA1c)Empagliflozin 10 mgEmpagliflozin 25 mgTotal
Mean8.83 ± 0.808.68 ± 0.878.76 ± 0.83
08

Study locations

16 sites
  • Kunisaki Makoto Clinic
    Fukuoka, Fukuoka, 819-0168, Japan
  • Seino I.M. Clinic, Fukushima, I.M.
    Fukushima, Koriyama, 963-8851, Japan
  • Nippon Kokan Fukuyama Hospital
    Hiroshima, Fukuyama, 721-0927, Japan
  • Nakakinen Clinic
    Ibaraki, Naka, 311-0113, Japan
  • Kubota Clinic
    Kanagawa, Kawasaki, 214-0014, Japan
  • Medical Corporation Yuga Higashirinkan Kaneshiro Diabetes Clinic
    Kanagawa, Yamato-shi, 242-0004, Japan
  • Yokohama Minoru Clinic
    Kanagawa, Yokohama, 232-0064, Japan
  • Yokkaichi Diabetes Clinic
    Mie, Yokkaichi, 510-0829, Japan
  • Shiraiwa Medical Clinic
    Osaka, Kashiwara-shi, 582-0005, Japan
  • AMC Nishi-umeda Clinic
    Osaka, Osaka-shi, 530-0001, Japan
  • OCROM Clinic
    Osaka, Suita, 565-0853, Japan
  • Fukuwa Clinic
    Tokyo, Chuo-ku, 103-0027, Japan
  • Tokyo-Eki Center-building Clinic
    Tokyo, Chuo-ku, 103-0027, Japan
  • Minamino Heart Clinic
    Tokyo, Hachioji, 192-0918, Japan
  • ToCROM Clinic
    Tokyo, Shinjuku-ku, 160-0022, Japan
  • Shinjuku Research Park Clinic
    Tokyo, Shinjuku-ku, 169-0073, Japan
09

References and documents

Publications

  • Terauchi Y, Utsunomiya K, Yasui A, Seki T, Cheng G, Shiki K, Lee J. Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study. Diabetes Ther. 2019 Jun;10(3):951-963. doi: 10.1007/s13300-019-0604-8. Epub 2019 Mar 25. PubMed 30912033 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Jun 2017, 19 months.

Results were first posted in Jan 2019, 1 year 7 months after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 19 months is close to that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2015
First posted
Oct 28, 2015
StartActual
Oct 29, 2015
Primary completionActual
Jun 2, 2017
CompletionActual
Jun 2, 2017
Results first posted
Jan 7, 2019
Last update
Jan 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02589626
Responsible party
Sponsor
First posted
Oct 28, 2015
Start date
Oct 29, 2015
Primary completion
Jun 2, 2017
Completion
Jun 2, 2017
Results posted
Jan 7, 2019
Last update
Jan 7, 2019

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion